A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies

Fujifilm Pharmaceuticals U.S.A., Inc.2 个研究点分布在 1 个国家目标入组 55 人开始时间: 2014年7月最近更新: 2025年3月19日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Fujifilm Pharmaceuticals U.S.A., Inc.
入组人数: 55
试验地点: 2
主要终点: Safety Assessed by Adverse Events

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A Phase 1/2a Dose Escalation Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and tolerability. A total of 6 cohorts will be enrolled in Phase 1 to establish the MTD. A total of 20 subjects with MDS/CMML treated at the RP2D are planned, including MDS/CMML subjects treated at the RP2D in Phase 1.

详细描述

Subjects will receive FF-10501-01 orally on a twice daily schedule for 14, 21 or 28 days repeated every 28 days (=1 cycle). Disease assessments, including analysis of blood and bone marrow aspirates, will be performed at the end of Cycle 1 and every 2 cycles thereafter. Subjects who demonstrate objective response or stable disease will be allowed to continue therapy with FF-10501-01 until progression of disease, observation of unacceptable adverse events, intercurrent illness or changes in condition that prevent further study participation.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Confirmed advanced hematologic malignancies;
•High-risk MDS/CMML (defined as ≥ 10% peripheral blood or marrow blasts and/or IPSS score ≥ 1.5) and relapsed or refractory to prior therapy
•AML relapsed or refractory to prior therapy, or ≥ 60 years of age and not a candidate for other therapies
•MDS/CMML, relapsed from, or refractory to, prior HMA therapy; the latter defined as failure to achieve clinical remission (CR), partial remission (PR) or hematologic improvement (HI) after previous HMA therapy (≥ 4 cycles of azacitidine or decitabine), or progression during, or toxicity to previous HMA therapy precluding further HMA treatment, and,
•Bone marrow blast count ≥ 10% or peripheral blast count ≥ 5%, or IPSS-R score ≥ 3.
•At least 3 weeks beyond the last chemotherapy, targeted anticancer agent, major surgery or experimental treatment and recovered from all acute toxicities (≤ Grade 1). Hydroxyurea used to control peripheral blast counts is permitted up to Day 7 of treatment on study.
•Adequate performance status: ECOG ≤ 2;
•Adequate renal and hepatic function:
•creatinine ≤ 2.0 mg/dL, or calculated creatinine clearance ≥ 45 mL/min
•total bilirubin ≤ 2 times the upper limit of normal (ULN)
•ALT/AST ≤ 2 times ULN
•Negative serum pregnancy test
•Ability to provide written informed consent

排除标准

•Known history of coronary artery disease, angina, myocardial infarction, congestive heart failure, cardiac arrhythmia or any other type of heart disease present within the last 6 months
•Known family history of hereditary heart disease
•QT interval corrected for rate (QTc) > 450 msec on the electrocardiogram (ECG) obtained at Screening
•Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, with the exception of anti-microbials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for the care of the patient.
•Presence of active central nervous system (CNS) leukemia. Subjects adequately treated for CNS leukemia documented by 2 consecutive cerebrospinal fluid samples negative for leukemia cells are eligible. Subjects with no history of CNS leukemia will not be required to undergo cerebrospinal fluid sampling for eligibility.
•Known positive for HIV, hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV).
•Active infection requiring IV anti-infective usage within the last 7 days prior to study treatment.
•Any other medical intervention or condition which could compromise adherence to study requirements or confound the interpretation of study results.
•Pregnant or breast-feeding.
•Treatment with any investigational product within 28 days prior to Screening.